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Abstract: The immense clinical and scientific benefits of cardiovascular imaging are well-
established, but are also true that 30 to 50% of all examinations are partially or totally 
inappropriate. Marketing messages, high patient demand and defensive medicine, lead to the 
vicious circle of the so-called Ulysses syndrome. Mr. Ulysses, a typical middle-aged 
“worried-well” asymptomatic subject with an A-type coronary personality, a heavy (opium) 
smoker, leading a stressful life, would be advised to have a cardiological check-up after 10 
years of war. After a long journey across imaging laboratories, he will have stress echo, 
myocardial perfusion scintigraphy, PET-CT, 64-slice CT, and adenosine-MRI performed, 
with a cumulative cost of >100 times a simple exercise-electrocardiography test and a 
cumulative radiation dose of >4,000 chest x-rays, with a cancer risk of 1 in 100. Ulysses is 
tired of useless examinations, exorbitant costs. unaffordable even by the richest society, and 
unacceptable risks. 
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1. Introduction 
 
Every year five billion imaging tests are performed worldwide, and about half of these are 
cardiovascular examinations [1]. According to recent estimates, at least one-third of all examinations 
are partially or totally inappropriate, i.e. risks and costs outweigh benefits [2]. A survey of the Italian 
Association of Echocardiography showed that 50% of resting transthoracic echocardiograms are 
totally or partially inappropriate [3]. The inappropriateness rate of coronary angiography has been 
described to be as high as 65% in some tertiary care referral centers [4]. The inappropriate testing rate 
in high-volume, tertiary care referral center was 28% for stress echo [5] and 36% for stress perfusion 
scientigraphy [6], and rose to 43% when no screening of external referral was implemented [5]. In a 
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Finnish CT study, up to 77% of CT examinations of the lumbar spine were not justified [7]. The 
number of appropriate cardiac CT examinations is still today around 20%, and was around 30% a few 
years ago [8]. Following the definition of the American College of Cardiology Foundation, an 
appropriate imaging study is one in which the expected incremental information, combined with 
clinical judgement, exceeds any expected negative consequences by a sufficiently wide margin for a 
specific indication that the procedure is generally considered acceptable care and a reasonable 
approach for the indication [9] (Figure 1). Negative consequences include the risks of the procedure 
itself (i.e., radiation or contrast exposure) and the downstream impact of poor performance such as 
delay in diagnosis (false negatives) or inappropriate diagnosis (false positives). This implies potential 
harm for patients undergoing imaging (who take the risks of an imaging study without a commensurate 
benefit), excessive delay in the waiting lists for other patients needing the examination and an 
exorbitant cost for society, with no improvement and possibly with a reduction in care quality [9].  
 
Figure 1. The balance between risks (red triangle) and benefits (green circles) determining 
the appropriateness score of testing. The three corners of the red triangle represent acute, 
subacute, and long-term (radiation) risks. Acute risks occur within seconds and minutes 
(for instance, death or myocardial infarction during stress or cath); sub-acute risks within 
days or weeks (for instance, contrast-induced nephropathy); and long-term risks (due to 
cumulative exposure to ionizing radiation) after years or decades. 
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As recently pointed out by Redberg, health care costs in the United States now exceed two trillion 
dollars, representing 16% of the country’s gross domestic product by 2016, and, in the words of 
Greenspan, are on “an unsustainable trajectory” [10]. Since 1993 cardiac imaging in individuals 
covered by Medicare has increased at an annual rate of 6.1%. Diagnostic imaging has increased more 
rapidly than any other component of medical care [4]. The volume of cardiovascular services increased 
5.5% per capita between 2004 and 2005 in the United States, driven largely by the growth of cardiac 
imaging services [10]. Although the diagnostic and prognostic information provided by these tests is 
not without a cost, some studies have shown that the use of non-invasive imaging in appropriately 
selected patients translates into savings because of more appropriate selection of even more expensive 
procedures [11,12]. However, these studies involved patients who were appropriately selected for 
testing; and the trade-off between costs and benefits will not be the same when studies are performed 
less appropriately [13]. In order to limit the detrimental consequences of the pandemic of 
inappropriateness and diagnostic obesity, the U.K. College of Radiology in 1999 [14], the European 
Commission in 2001 [15], and more recently the American College of Cardiology [9] have prepared 
guidelines on appropriateness of general or specialized imaging testing, including stress perfusion 
scintigraphy [16] and stress echocardiography [17]. The ultimate goal of these documents is to define 
the appropriate test for the appropriate indication in the appropriate patient: a difficult, elusive and 
moving target which is however one of the new features, and not the least important, of good quality 
medical care [9,15]. 
 
2. The Ulysses Syndrome in the Cardiac Imaging Lab 
 
The Ulysses syndrome was first described in 1972 by Canadian physician Dr. Mercer Rang, who 
applied it to the ill effects of extensive diagnostic investigations conducted because of a false-positive 
or indeterminate result in the course of a routine laboratory screening [18]. Ulysses left Troy in full 
physical and psychological health. Equipped with a safe ship and a competent crew, he was sure he 
would return home quickly; instead it turned out that he lost all his crew, his ship and he was able to 
make it home only after a journey full of hardships. Today, the most frequent diagnostic investigation 
is a cardiac imaging test. Mr. Ulysses, a typical middle-aged “worried-well” asymptomatic subject 
with an A-type coronary personality, a heavy (opium) smoker, leading a stressful life, would be 
advised to have a cardiological check-up after 10 years of war (Figure 2). In an asymptomatic patient, 
routine screening even with a simple exercise testing is not indicated (class III). The indication is IIB 
(weak supportive evidence) for asymptomatic men older than 45 years with multiple risk factors and/or 
who are involved in occupations in which impairment might impact public safety, according to 2003 
recommendations of the American College of Cardiology/American Heart Association [19]. The 
family physician directly refers the patient to the cardiologist (step 2) who suggests a transthoracic 
echocardiogram (step 3), which is perfectly normal, but with poor visualization of segment 17, the true 
apex. The patient is again sent to the echo lab to repeat the transthoracic echo with echo-contrast 
injection (step 4): the apex is perfectly visualized and looks normal. However, just to be on the safe 
side, the cardiologist suggests a multislice computed tomography (step 5). Ulysses accepts 
enthusiastically since he recently read the front page and cover story of Time Magazine (September 5, 
2005) explaining that in this way you can detect asymptomatic life-threatening coronary artery 
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stenosis. The scan shows only minor luminal irregularities of very uncertain pathological meaning. At 
this point, thallium stress perfusion scintigraphy (step 6) is performed. A very mild, questionable 
hypoperfusion of the infero-basal wall is documented. The stress echo (step 7) is performed and a very 
mild apical hypokinesis is observed at peak exercise in presence of marked systolic blood pressure 
rise. At this point the cardiologist asks for further examinations and Mr. Ulysses is becoming 
increasingly anxious. One after another, Ulysses undergoes a PET-adenosine stress (step 8: marginally 
positive at basal lateral wall) and MRI adenosine with gadolinium contrast (step 9: marginally positive 
on the basal inferior septum). The patient is eventually referred to coronary angiography (step 10); the 
island of Ithaca is crowded with non-significant coronary stenoses, unrelated to perfusion defects or 
wall motion abnormalities, which may, however, trigger the oculo-stenotic reflex [10] leading to the 
vicious circle of angioplasty (obviously with drug-eluting stent), imaging test for the diagnosis of 
silent re-stenosis, presence of perfusion or wall motion defects, re-angiography, and so on and so forth.  
 
Figure 2. Ulysses’ voyage as a metaphor for the diagnostic pathway of the patient with 
suspected coronary artery disease. At the end of the first round of this odyssey, the 
cumulative cost is more than 100 times a simple exercise-electrocardiography. The 
cumulative radiation dose is that of more than 4,000 chest x-rays. The cumulative damage 
(including acute, subacute, and long-term risks) will cause a serious health detriment 
(including infarction, renal insufficiency, or cancer) in about 5-10% of patients. 
 
 
None of these examinations are free, and each implies a financial and a safety cost. For a resting 
cardiac imaging test, taking the average cost (not charges) of an echocardiogram as equal to 1 (as a 
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cost comparator), the cost of a CT is 3.1x, of a SPECT 3.2x, of a cardiovascular magnetic resonance 
imaging 5.51x, of a PET scan 14.03x and of a right and left heart catheterization 19.95x [20]. For 
stress cardiac imaging, compared with the treadmill exercise test considered as equal to 1 (as a cost 
comparator), the cost of a stress scintigraphy is 2.1x, and of a stress SPECT scintigraphy 5.7x [19].  
There are non-negligible acute risks in several non-invasive imaging techniques. Exercise testing 
entails a very small but definite risk, and data confirm that up to 1 myocardial infarction or death per 
2,500 tests occurs [19]. Major, life-threatening side effects (sustained ventricular tachycardia, 
ventricular fibrillation and myocardial infarction) occur in about 1 out of 300 dobutamine-
echocardiography and 1 out of 1,000 dipyridamole-echocardiography tests [21-23]. In general, 
exercise is safer than pharmacological stress, in which major complications are three times more 
frequent with dobutamine than with dipyridamole [24,25]. 
The use of nephrotoxic contrast in large doses with radiologic imaging is a major concern, since it 
induces an acute worsening of renal function – not always reversible – in about 10% of patients with 
impaired renal function [26]. Also with echocardiography, the use of contrast may add an extra risk of 
about 1 in 10,000 of allergic and life-threatening [27] reactions, and – experimentally – the number of 
injured cardiomyopathies increased with increasing contrast agent dose and ultrasound exposure [28], 
possibly due to acoustic cavitation and acoustic current production which may locally deliver high 
levels of mechanical energy (higher with increasing power output, mirrored by the mechanical index). 
Minor side effects (probably due to microembolization of injected bubbles) are frequent in up to 10% 
of patients, and include headache, nausea and vomiting, dysgeusia and dyspnea. Major life-threatening 
side effects are rare but possible, and consist of ventricular tachycardia, pulmonary edema, ventricular 
fibrillation and even death. Toxic effects led the FDA to force manufacturers to add a “boxed warning” 
on Luminity in October 2007, stating that “4 deaths and 110 various non-fatal reactions occurred 
during or 30’ after the infusion (out of about 2 million studies)” [28,29]. Recently, additional concern 
arose regarding the use of paramagnetic contrast during CMR in patients with impairment of renal 
function. Paramagnetic contrast agents have long been considered absolutely safe and well tolerated. 
However, in May 2007, the FDA (and EMEA) ordered a boxed warning on the safety of gadolinium-
containing contrast agents, on the basis of 200 cases of nephrogenic systemic fibrosis (NSF) that 
occurred in patients with kidney failure. NSF (also called nephrogenic fibrosing dermopathy, NFD) 
causes the patient to develop tight and rigid skin making it difficult to bend joints. NSF/NFD may also 
result in fibrosis, or sclerosis, of body organs resulting in the inability of body organs to work properly 
and can lead to death [30]. Risks are acute (linked to stress), subacute (linked to contrast use) and long-
term (linked to radiation): Table 1. 
The rate of complications is obviously higher with invasive imaging procedures. For instance, 
coronary angiography has a cumulative risk of 1-2% of major complications (including dissection, 
myocardial infarction, stroke) and 1 in 1,000 risk of death [26]. Contrast-induced nephropathy is the 
third most common cause of hospital-acquired renal failure, ranging between 3 and 14% in patients 
with cardiovascular pathology undergoing angiography procedures [26]. All of these risks may be 
fully acceptable in presence of a proper indication, but become totally unacceptable if the indication is 
less than appropriate. More than 10 million stress imaging procedures [31] and more than one million 
coronary angiographies [31] are performed every year in the USA alone. The small individual risk thus 
becomes an important population burden. 
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Table 1. Acute, subacute, and long-term risks in cardiac imaging. 
 ACUTE SUBACUTE CHRONIC 
Most frequent cause Stress Iodinated contrast Radiation 
Timing Seconds Days Years 
Examples Myocardial infarction Renal failure Cancer 
Cellular target Endothelium of 
coronary arteries 
Kidney tubular cell Somatic cells (lung, 
breast, bone marrow) 
Risk per exam 1 in 500-1 in 1,000 1 in 50-1 in 100 1 in 500-1 in 1,000 
Cumulative nature No No yes 
 
Besides these clearly recognized acute and subacute risks, long-term risks linked to imaging 
radiation should also be considered [32]. Medical x-rays and γ-rays are a proven human carcinogen 
[14,15,33]. In radiology and nuclear medicine, higher acute doses correspond to higher long-term 
risks; there are no safe doses, and all doses add up in determining the cumulative risks over a lifetime 
[14,15,34]. Doses of common imaging are reported in yellow in Figure 2, and range from the 
equivalent of 300 chest x-rays of a coronary angiography to that of 1,250 chest x-rays of a thallium or 
PET-CT scan [35]. With imaging cumulative doses (radiation expenditure), the patient “buys” 
increasing risks of developing cancer during their lifetime. The estimated risk of developing cancer, 
based on the Seventh Report of the authorative Committee to Assess Health Risks from Exposure to 
Low Levels of Ionizing Radiation (BEIR VII report) linear nothreshold model [33], is presented in 
Figure 3. 
As an example, the attributable risk of cancer for a multislice computed tomography give a dose 
equivalent to about 750 chest x-rays with a lifetime extra-risk of 1 cancer in 750 of exposed adult 
males, 1 in 500 of exposed adult females, and 1 in 100 in female children aged less than 1 year. 
In other words, at the end of the first round of examinations shown in Figure 2, Ulysses has paid 
about 100 times the cost of a simple exercise-electrocardiography test – probably even that not needed 
[19]. He received a 5% cumulative risk of major short-term adverse events (from renal insufficiency to 
myocardial infarction). He received a cumulative dose exposure of about 4,000 chest x-rays, 
corresponding to an extra-risk of cancer of 1 in 150. The invasive and interventional procedures that he 
received did not improve his quality of life since he was asymptomatic at the beginning of his 
cardiological history and the anatomy-driven revascularization will not increase his life expectancy 
[19,36,37]. Periodic follow-up examinations with imaging testing will be scheduled – mostly 
inappropriately [15,6] - and the Odyssey will last probably forever. 
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Figure 3. On the x axis, the doses of 4 common imaging examination are shown: coronary 
angiography (250 chest x-rays); myocardial perfusion scintigraphy (500 chest x-rays);  
64-slice CT (750 chest x-rays); whole body CT- PET scan (1,250 chest x-rays). On y-axis 
risk for children (male and female), adults (men and women) and the elderly. Redrawn and 
modified from ref. [35]. 
 
 
Figure 4. Inappropriateness in stress echocardiography (left) and cardiac stress imaging 
(right). Data are derived from [5] (Pisa and Brisbane echo labs in Italy and Australia) and 
[6] (Mayo Clinic nuclear cardiology lab in the USA). 
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3. Appropriateness in Cardiac Stress Imaging 
 
The proliferation of cardiac stress imaging may represent an added value when appropriate, and an 
added cost when inappropriate. Unfortunately, the definition of appropriateness is obvious in theory, 
but not so straightforward on practical grounds. Unlike prevention and treatment strategies supported 
by evidence-based practice guidelines, the evidence base for imaging is anecdotal, fragmented, and 
lacking in prospective clinical trials [9]. As a consequence, the process for developing appropriateness 
criteria is only partially evidence-based and is heavily weighted by expert consensus [9]. On an 
arbitrary scale of 1 (most inappropriate) to 9 (most appropriate), indications are classified as 
“appropriate” (score >7, test is generally acceptable and is a reasonable approach for the indication), 
“uncertain” (score between 4 and 6, test may be generally acceptable and may be a reasonable 
approach for the indication), and “inappropriate” (score <3, test is not generally acceptable and is not a 
reasonable approach for the indication). The most frequent appropriate, uncertain and inappropriate 
indications met in the clinical practice of high volume laboratories are listed in Table 2. Following 
these criteria, only 2 out of 3 stress echo (or nuclear stress imaging) tests are appropriate, with similar 
numbers observed in disparate geographic, cultural and economic situations – from Italy to Australia 
[5] to the USA [6]. Of interest, the vast majority of inappropriate studies were restricted to only a few 
patient indications, with the four most frequent inappropriate indications listed in Table 2 account for 
88% of all inappropriate examinations [38]. This repetitive pattern of inappropriateness points to a 
need for quality improvement and educational programs to achieve measurable improvement in results 
[38]. This is especially important today and in view of the projected spectacular rise of cardiac 
imaging in the next 15 years [39] (Figure 5).  
 
Figure 5. Future trends in the use of cardiac imaging up to the year 2020. Redrawn from 
the original data of reference [35]. 
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Table 2. Most frequent appropriate/uncertain/inappropriate indications of cardiac stress 
imaging (with echo or nuclear) in CAD detection and/or risk stratification. 
 Appropriate Uncertain Inappropriate 
ECG uninterpretable or unable to exercise, or prior stress 
ECG equivocal 
√   
Coronary artery stenosis of unclear significance (CT or 
angio) 
√   
Post-revascularization not in the early post-procedure 
period, with change in symptoms 
√   
Pre-surgery, high risk non-emergent, poor exercise 
tolerance <4 METS 
√   
Viability (dobutamine) Ischemic cardiomyopathy, known 
CAD, pt eligible for revascularization 
√   
Asymptomatic or stable symptoms, repeat stress echo 
after > 5 yrs 
 √  
Asymptomatic < 5 yrs post CABG or < 2 yrs post-PCI  √  
Asymptomatic, low risk   √ 
Pre-op, intermediate risk surgery, good exercise capacity   √ 
Symptomatic, low pre-test probability, interpretable 
ECG, able to exercise 
  √ 
Pre-op, low-risk surgery 
 
It is certainly good to have multiple imaging tools, which allow us to avoid the contraindications 
and limitations of each technique and to tailor the best (most effective) test in individual patients. The 
best test choice should also consider the test with the lowest cost – for any given accuracy – and, 
importantly, the test with the lowest acute, chronic and long-term risks. This concept is clearly spelled 
out in guidelines of the U.K. College of Radiology in 1999 [24], Medical Imaging Guidelines in 2001 
[15], and the American College of Cardiology Guidelines in 2006 [16,17]. 
For instance, with special regard to the radiation issue, European Union guidelines state that “for 
instance, because MRI does not use ionizing radiation, MRI should be preferred when both CT and 
MRI would provide similar information and when both are available”. The American College of 
Cardiology definition of appropriateness defines an imaging study as “one in which the expected 
incremental information exceeds the negative consequences, which include the risks of the procedure 
(i.e., radiation or contrast exposure) and the downstream impact of poor test performance”.  
Imaging technology evolution in the last 30 years was characterized by a shift from 1-dimensional 
(1970s) to a 2-dimensional (1980s-90s) and current 3-dimensional representation of the heart provided 
by all major imaging modalities. Probably, the evolution of technology has not always been fully 
matched by our maturity in using it. We should probably move from a 1-dimensional approach to 
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imaging (typical of the 1980s) to the 2-dimensional approach (considering cost-effectiveness, not only 
effectiveness) up to a three-dimensional approach integrating benefit, cost, and risk. 
Appropriateness in health care, like quality, can be a moving target and not easy to define. 
However, it is also true that, as with many quality measures, the very act of having appropriateness 
criteria and measuring your own appropriateness performance is likely to improve the quality of what 
is being measured [38]. This needs to be done to improve the quality of our profession, to address the 
existing concerns of those who pay for these services, and to optimize the immense benefits our 
patients can derive from the appropriate practice of cardiac imaging [40]. 
 
4. The Risks of Unawareness  
 
Good medical practice warrants knowledge of the doses and long-term risks of these tests – which 
can be judiciously employed when they are most appropriate. Unfortunately, recent evidence shows 
that such radiological awareness is uncommon. The results of a survey performed on British 
physicians shows that one out of 20 doctors does not realise that ultrasound does not use ionizing 
radiation, that one out of 10 does not realise that magnetic resonance imaging does not use ionizing 
radiation, and 97% of doctors grossly underestimate (on average by sixteen-fold) the doses of radiation 
for most commonly requested investigations [41]. Another survey on Israeli orthopedists shows that 
the mortality risk of radiation induced carcinoma from bone scan was identified correctly by less than 
5% of respondents and senior orthopedists estimated lower risks than did residents [42]. A third survey 
was performed on Emergency Room physicians and radiologists in a U.S. academic centre. Almost all 
doctors were unable to accurately estimate the dose for a computed tomography scan compared with 
that for one chest radiograph. Among radiologists, 5% of respondents thought that a computed 
tomography scan dose was less than one chest radiograph, and 56% estimated the computed 
tomography scan dose between 1 and 10 chest radiographs, with dramatic underestimation of the true 
dose (about 500 chest radiographs) [43]. In another survey conducted in a tertiary care referral centre 
of adult and pediatric cardiology, Correia et al. found that 95% of physicians wrongly underestimated 
the risk of fatal cancer associated with a stress myocardial perfusion scintigraphy. The correct dose of 
a stress sestamibi myocardial scintigraphy (corresponding to 500 chest x-rays) was correctly estimated 
by 29% of physicians, whereas 71% wrongly estimated the dose exposure as equal to one (13% of 
respondents), or one half (9%) or three times (49%) that of a chest x-ray [44]. If risks are ignored, all 
examinations become appropriate: benefit without risk. The dose information should be expressed 
clearly for each and every examination, especially in cardiology, where many examinations with high 
radiation dose are performed many times. Table 3 summarizes doses and risks of common 
cardiological examinations. Doses are reported from European Union Medical Imaging guidelines [15] 
and Royal College of Radiology 2007 [45], and coronary stenting and thallium scan doses updated 
from latest American Heart Association document [40]. This information is something that everyone, 
including patients, should know, and almost everyone – including physicans - ignore.  
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Table 3. Dose/Risk Communication The Royal College of Radiologists approach (RCR). 
Investigation Effective Dose 
(mSv) 
Equivalent 
No. of Plain 
Chest 
Radiographs 
Approximate 
Equivalent 
Period of 
Natural 
Background 
Radiation 
Additional 
Lifetime 
Risk of 
Fatal and 
Non-Fatal 
Cancer* 
RCR Symbolic 
Representation** 
Plain PA chest 
radiograph 
 
0.02 
 
1 
 
3 days 
 
1:1,000,000 
 
 
Lung perfusion 
scintigraphy (Tc99m) 
 
1 
 
50 
 
6 months 
 
1:10,000 
 
CT chest (non contrast)  8 
 
400 
 
3.6 years 
 
1: 1,200   
Perfusion cardiac Rest-
stress Technetium 99m 
sestamibi scan 
10 500 4 years 1:1,000     
MDCT Cardiac (64- 
slice) 
 
15 
 
750 
 
7 years 
 
1:750   
Coronary stenting 20 1050 8 years 1:500     
Thallium-201 scan 41 2000 16 years 1:250  
 
*These examples relate to a 50 year-old male. Multiply by 1.38 for women, by 4 for children under 1 year, and by 0.5 in an 
80 year old male; ** : <1 mSv : 1 – 5 mSv, : 5 – 10 mSv, : > 10 mSv; On the right side column, 
symbology proposed by Royal College of Radiology, 2007 [45]. 
 
5. The Risks of Technology Underuse 
 
Advances in imaging technology have led to an explosive growth in the performance of 
cardiovascular imaging. This growth is challenging since it may lead overuse or inappropriate use of 
new technology. However, underuse of this technology is equally inappropriate. Radiation protection 
should not cause examinations needed to be refused or not performed. Justification is probably best 
made by a physician who is familiar with the patient’s medical history [46], and both justification and 
dose optimization are best implemented if a regular audit program is a part of the clinical practice [47]. 
However, the regular application of audit, awareness and appropriateness implementation is usually 
not facilitated by a health system that pays for volumes, not for appropriateness. New payment models 
should be developed to pay physicians more for providing clearly appropriate procedures and 
substantially less for procedures of limited value. Although it is certain that this is more easily said 
than done, there is no doubt that a system paying the quality, not only the quantity, of the procedures 
would be an enormous boost to appropriateness. 
 
6. Conclusions 
 
The benefits of diagnostic imaging are immense and have revolutionized the practice of medicine. 
The use of radiological investigations is an accepted part of the medical practice justified in terms of 
clear clinical benefits to the patient, and failure of providing services from which the patient would 
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likely benefit is dangerous. However, the unjustified use of diagnostic testing can be equally 
dangerous.  
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